IL-15 was discovered as a molecule highly related to interleukin-2 (IL-2), which reached the clinical setting as an approved biological drug in 1992 and was the first paradigm of successful immunotherapy of cancer [9,10]. The gene discussed is IL15; the disease is cancer.